Genmab A/S
Genmab A/S (GNMSF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
gnmsf · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $249.45
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $239.30 | ↓ 4.07% |
1-day model range: $238.12–$240.48. Peak: $240.48 (-4.07%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $233 | -6.7% |
| 2028 | $223 | -10.7% |
| 2029 | $216 | -13.2% |
| 2030 | $213 | -14.8% |
| 2031 | — | -15.8% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GNMSF · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-10-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-10-12 | BTIG | Maintains | Buy→Buy |
| 2023-09-25 | Truist Securities | Maintains | Buy→Buy |
| 2023-09-05 | Truist Securities | Maintains | Buy→Buy |
| 2023-09-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-03 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2023-08-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-07-31 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2023-07-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Genmab A/S (GNMSF) stock. Of the recent 71 rating actions, 2 were upgrades and 6 were downgrades. 11 analysts currently cover GNMSF.
Analyst Recommendation Trends
GNMSF analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$4.3B
↓ 29.0% YoY
Revenue Next Year
$5.1B
↑ 17.1% YoY
EPS This Year
$11.51
EPS Next Year
$16.72
↑ 45.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast GNMSF EPS of $11.51 for the current fiscal year, based on estimates from 10 analysts. The GNMSF revenue forecast is $4.3B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GNMSF stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GNMSF price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The GNMSF short-term stock prediction for tomorrow is $239.30 (-4.07%). The GNMSF stock price prediction for 2027 estimates an average of $233. The GNMSF stock prediction for 2030 projects a range of $201–$224.
Genmab A/S trades on OTC under the ticker GNMSF. The GNMSF stock outlook for 2027 is broadly positive, supported by a Buy consensus among 55% of covering analysts.
Frequently asked questions
GNMSF forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month GNMSF price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $249.45.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.